These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29244026)

  • 1. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
    Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
    Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
    Finberg RW; Lanno R; Anderson D; Fleischhackl R; van Duijnhoven W; Kauffman RS; Kosoglou T; Vingerhoets J; Leopold L
    J Infect Dis; 2019 Mar; 219(7):1026-1034. PubMed ID: 30428049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
    JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
    Deleu S; Kakuda TN; Spittaels K; Vercauteren JJ; Hillewaert V; Lwin A; Leopold L; Hoetelmans RMW
    Br J Clin Pharmacol; 2018 Nov; 84(11):2663-2672. PubMed ID: 30098042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
    Yogaratnam J; Rito J; Kakuda TN; Fennema H; Gupta K; Jekle CA; Mitchell T; Boyce M; Sahgal O; Balaratnam G; Chanda S; Van Remoortere P; Symons JA; Fry J
    J Infect Dis; 2019 Jan; 219(2):177-185. PubMed ID: 30053042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L; Treanor J; Gubareva L; Hayden FG
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
    Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
    J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
    Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
    JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study.
    O'Neil B; Ison MG; Hallouin-Bernard MC; Nilsson AC; Torres A; Wilburn JM; van Duijnhoven W; Van Dromme I; Anderson D; Deleu S; Kosoglou T; Vingerhoets J; Rossenu S; Leopold L
    J Infect Dis; 2022 Aug; 226(1):109-118. PubMed ID: 32604406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study.
    Vingerhoets J; Van Dromme I; van Duijnhoven W; Anderson D; De Meyer S; Leopold L
    Antivir Ther; 2023 Jun; 28(3):13596535231174273. PubMed ID: 37226302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral oseltamivir in human experimental influenza B infection.
    Hayden FG; Jennings L; Robson R; Schiff G; Jackson H; Rana B; McClelland G; Ipe D; Roberts N; Ward P
    Antivir Ther; 2000 Sep; 5(3):205-13. PubMed ID: 11075941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Sloan SE; Szretter KJ; Sundaresh B; Narayan KM; Smith PF; Skurnik D; Bedard S; Trevejo JM; Oldach D; Shriver Z
    Antiviral Res; 2020 Dec; 184():104763. PubMed ID: 32151645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.
    Whitley R; Laughlin A; Carson S; Mitha E; Tellier G; Stich M; Elder J; Alexander WJ; Dobo S; Collis P; Sheridan WP
    Antivir Ther; 2015; 20(7):709-19. PubMed ID: 25318121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
    N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685.
    Al-Nakib W; Higgins PG; Willman J; Tyrrell DA; Swallow DL; Hurst BC; Rushton A
    J Antimicrob Chemother; 1986 Jul; 18(1):119-29. PubMed ID: 3531141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.
    Deng R; Lee AP; Maia M; Lim JJ; Burgess T; Horn P; Derby MA; Newton E; Tavel JA; Hanley WD
    Clin Pharmacokinet; 2018 Mar; 57(3):367-377. PubMed ID: 28639229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.